This systematic literature review evaluated the clinical efficacy and safety of interventions used in relapsed/refractory follicular lymphoma. Primary efficacy outcomes were objective response rate, progression-free survival and overall survival. Safety endpoints were grade 3/4 toxicities, serious adverse events and withdrawals or deaths due to toxicity. Studies were selected if they were randomized controlled trials reporting on the efficacy or safety of treatments for relapsed or refractory follicular lymphoma, and if outcomes were reported separately from trials that included other lymphoid neoplasms. We used the Bucher method for conducting adjusted indirect comparisons within a meta-analysis. We identified 10 randomized controlled trials of treatments for relapsed/refractory follicular lymphoma. The most prominent drug investigated (alone or in combination) was rituximab. Most trials did not report median overall survival. Two trials reported median event-free survival (range, 1.2-23.2 months). Six of ten trials reported objective response rate (range, 9–93%). Meta-analysis showed only one statistically significant result: rituximab + bortezomib yielded a significantly higher objective response rate than rituximab monotherapy (relative risk, 1.28; 95% confidence interval, 1.11–1.47). Otherwise, there were no discernable differences in overall survival or progression-free survival, partly due to insufficient reporting of results in the clinical trials. The relatively small number of randomized controlled trials, few overlapping treatment arms, and variability in the randomized controlled trial features and in the endpoints studied complicate the formal comparison of therapies for relapsed/refractory follicular lymphoma. Additional well-designed randomized controlled trials are needed to fully understand the relative outcomes of older and more recently developed therapies.
BucherHCGuyattGHGriffithLE. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol1997; 50: 683–691.
8.
RobakTBlonskiJZKasznickiM. Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia – updated results of the multicentre study of 378 patients. Br J Haematol2000; 108: 357–368.
9.
RobakTBlonskiJZKasznickiM. The effect of subsequent therapies in patients with chronic lymphocytic leukemia previously treated with prednisone and either cladribine or chlorambucil. Haematologica2005; 90: 994–996.
O’BrienSMooreJOBoydTE. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol2007; 25: 1114–1120.
12.
CoiffierBOsmanovEAHongX. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol2011; 12: 773–784.
13.
Coiffier B, Osmanov E, Hong X, et al. Bortezomib-rituximab results in improved PFS and response rates versus rituximab, and quality of response is associated with improved outcomes, in patients with relapsed follicular lymphoma (FL). In: Presented at the 16th congress of the European hematology association, London, UK, 9–12 June 2011.
14.
Rothman M, Pei L, Ganguly R, et al. Patient-reported outcomes during and following treatment with bortezomib plus rituximab or rituximab alone in patients with relapsed follicular lymphoma (FL): results from a phase 3 study. In: Presented at the 16th congress of the European hematology association, London, UK, 9–12 June 2011.
Coiffier B, Osmanov E, Hong X, et al. A phase 3 trial comparing bortezomib plus rituximab with rituximab alone in patients with relapsed, rituximab-naive or -sensitive, follicular lymphoma. In: Presented at the ASH Annual Meeting, Orlando, FL, 4–7 December 2010.
17.
GhielminiMSchmitzSFCogliattiSB. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood2004; 103: 4123–4416.
18.
Leonard J, Jung S, Johnson J, et al. CALGB 50401: a randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. In: Presented at the 2012 ASCO annual meeting, Chicago, IL, 1–5 June 2012.
19.
Van OersMHKlasaRMarcusRE. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood2006; 108: 3295–3301.
20.
Van OersMHVan GlabbekeMGiurgeaL. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol2010; 28: 2853–2858.
21.
WitzigTEGordonLICabanillasF. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol2002; 20: 2453–2463.
22.
Gómez Almaguer D, Aung S, Kotb R, et al. Inotuzumab ozogamicin plus rituximab versus defined investigator’s choice in CD20+/CD22+ follicular non-Hodgkin lymphoma. In: Presented at the 17th congress of the European hematology association, Amsterdam, Netherlands, 14–17 June 2012.
23.
NCT00268983. Comparison of rituximab versus tositumomab and iodine I 131 tositumomab (BEXXAR® therapeutic regimen) for patients with relapsed follicular non-Hodgkins lymphoma, www.clinicaltrials.gov/ct2/show/NCT00268983?term=NCT00268983&rank=1. (accessed 8 December 2012.).
Goy A, Offner F, Martinelli G, et al. Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: preliminary analysis of the GAUSS study. In: Presented at the 17th congress of the European hematology association, Amsterdam, Netherlands, 14–17 June 2012.
27.
Sehn LH, Goy A, Offner FC, et al. Randomized phase II trial comparing GA101 (obinutuzumab) with rituximab in patients with relapsed CD20 indolent B-cell non-Hodgkin lymphoma: preliminary analysis of the GAUSS study. In: Presented at the ASH annual meeting, San Diego, CA, 10–13 December 2011.
28.
LaportGG. Changing role of stem cell transplantation in follicular lymphoma. Hematology Am Soc Hematol Educ Program2012; 2012: 417–425.
29.
DreylingMGhielminiMMarcusR. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol2014; 25(Suppl 3): iii76–iii82.
30.
YounesAThieblemontCMorschhauserF. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol2014; 15: 1019–1026.
31.
GopalAKKahlBSde VosS. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med2014; 370: 1008–1018.
MontotoSCorradiniPDreylingM. Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Haematologica2013; 98: 1014–1021.
34.
VillaDCrumpMPanzarellaT. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group. J Clin Oncol2013; 31: 1164–1171.
35.
ChesonBDBennettJMGreverM. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood1996; 87: 4990–4997.
